Irving W. Wainer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Irving W. Wainer has a total of 149 co-authors. Here are the top co-authors by number of shared publications:
Ruin Moaddel
Laboratory of Clinical Investigation, National Institute on Aging Intramural Research Program, National Institutes of Health, Baltimore, MD, USA
19 shared publications- Michel Bernier
Experimental Gerontology Section, Translational Gerontology Branch, National Institute on Aging, NIH
12 shared publications - Krzysztof Jozwiak
Department of Biopharmacy, Medical University of Lublin, Lublin, Poland
9 shared publications Anuradha Ramamoorthy
Laboratory of Clinical Investigation, Division of Intramural Research Programs, National Institute on Aging, National Institutes of Health Baltimore, Maryland, 21224
6 shared publicationsMarc C. Torjman
Department of Anesthesiology, Cooper Medical School of Rowan University, Camden, USA
6 shared publicationsJohn Caldwell
Division of Biomedical Sciences, Imperial College School of Medicine, London, UK
4 shared publications
Latest Publications
- 1 September 2017
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 144
Preface
- 1 September 2017
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 144
Preface
- Open Access
- 3 July 2015
- Published by Wiley in British Journal of Pharmacology
- Vol. 172 (18) , 4546-4559
Enantioselective inhibition of d‐serine transport by (S)‐ketamine
Background and Purpose Patients with major depressive disorder receiving racemic ketamine, (R,S)‐ketamine, experience transient increases in Clinician‐Administered Dissociative States Scale scores and a coincident drop in plasma d‐serine levels. The results suggest that (R,S)‐ketamine produces an immediate, concentration‐dependent pharmacological effect on d‐serine plasma concentrations. One potential source of this effect is (R,S)‐ketamine‐induced inhibition of the transporter ASCT2, which regulates intracellular d‐serine concentrations. In this study, we tested this hypothesis by examining the effect of (S)‐ and (R)‐ketamine on ASCT2‐mediated transport of d‐serine in PC‐12 and 1321N1 cells and primary neuronal cells in culture. Experimental Approach Intracellular and extracellular d‐serine levels were determined using capillary electrophoresis–laser‐induced fluorescence and liquid chromatography–mass spectrometry respectively. Expression of ASCT2, Asc‐1 and serine racemase was determined utilizing Western blotting. Key Results (S)‐Ketamine produced a concentration‐dependent increase in intracellular d‐serine and reduced extracellular d‐serine accumulation. In contrast, (R)‐ketamine decreased both intracellular and extracellular d‐serine levels. The ASCT2 inhibitor, benzyl‐d‐serine (BDS), and ASCT2 gene knockdown mimicked the action of (S)‐ketamine on d‐serine in PC‐12 cells, while the Asc‐1 agonist d‐isoleucine reduced intracellular d‐serine and increased extracellular d‐serine accumulation. This response to d‐isoleucine was not affected by BDS or (S)‐ketamine. Primary cultures of rat neuronal cells expressed ASCT2 and were responsive to (S)‐ketamine and BDS. (S)‐ and (R)‐ketamine increased the expression of monomeric serine racemase in all the cells studied, with (S)‐ketamine having the greatest effect. Conclusions and Implications (S)‐Ketamine decreased cellular export of d‐serine via selective inhibition of ASCT2, and this could represent a possible source of dissociative effects observed with (R,S)‐ketamine.
- 3 July 2015
- Published by Wiley in British Journal of Pharmacology
- Vol. 172 (18) , 4546-4559
Open AccessEnantioselective inhibition of d‐serine transport by (S)‐ketamine
Background and Purpose Patients with major depressive disorder receiving racemic ketamine, (R,S)‐ketamine, experience transient increases in Clinician‐Administered Dissociative States Scale scores and a coincident drop in plasma d‐serine levels. The results suggest that (R,S)‐ketamine produces an immediate, concentration‐dependent pharmacological effect on d‐serine plasma concentrations. One potential source of this effect is (R,S)‐ketamine‐induced inhibition of the transporter ASCT2, which regulates intracellular d‐serine concentrations. In this study, we tested this hypothesis by examining the effect of (S)‐ and (R)‐ketamine on ASCT2‐mediated transport of d‐serine in PC‐12 and 1321N1 cells and primary neuronal cells in culture. Experimental Approach Intracellular and extracellular d‐serine levels were determined using capillary electrophoresis–laser‐induced fluorescence and liquid chromatography–mass spectrometry respectively. Expression of ASCT2, Asc‐1 and serine racemase was determined utilizing Western blotting. Key Results (S)‐Ketamine produced a concentration‐dependent increase in intracellular d‐serine and reduced extracellular d‐serine accumulation. In contrast, (R)‐ketamine decreased both intracellular and extracellular d‐serine levels. The ASCT2 inhibitor, benzyl‐d‐serine (BDS), and ASCT2 gene knockdown mimicked the action of (S)‐ketamine on d‐serine in PC‐12 cells, while the Asc‐1 agonist d‐isoleucine reduced intracellular d‐serine and increased extracellular d‐serine accumulation. This response to d‐isoleucine was not affected by BDS or (S)‐ketamine. Primary cultures of rat neuronal cells expressed ASCT2 and were responsive to (S)‐ketamine and BDS. (S)‐ and (R)‐ketamine increased the expression of monomeric serine racemase in all the cells studied, with (S)‐ketamine having the greatest effect. Conclusions and Implications (S)‐Ketamine decreased cellular export of d‐serine via selective inhibition of ASCT2, and this could represent a possible source of dissociative effects observed with (R,S)‐ketamine.
- Open Access
- 22 June 2015
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 3 (4) , e00157
The distribution and clearance of (2S,6S)‐hydroxynorketamine, an active ketamine metabolite, in Wistar rats
The distribution, clearance, and bioavailability of (2S,6S)‐hydroxynorketamine has been studied in the Wistar rat. The plasma and brain tissue concentrations over time of (2S,6S)‐hydroxynorketamine were determined after intravenous (20 mg/kg) and oral (20 mg/kg) administration of (2S,6S)‐hydroxynorketamine (n = 3). After intravenous administration, the pharmacokinetic parameters were estimated using noncompartmental analysis and the half‐life of drug elimination during the terminal phase (t1/2) was 8.0 ± 4.0 h and the apparent volume of distribution (Vd) was 7352 ± 736 mL/kg, clearance (Cl) was 704 ± 139 mL/h per kg, and the bioavailability was 46.3%. Significant concentrations of (2S,6S)‐hydroxynorketamine were measured in brain tissues at 10 min after intravenous administration, ~30 μg/mL per g tissue which decreased to 6 μg/mL per g tissue at 60 min. The plasma and brain concentrations of (2S,6S)‐hydroxynorketamine were also determined after the intravenous administration of (S)‐ketamine, where significant plasma and brain tissue concentrations of (2S,6S)‐hydroxynorketamine were observed 10 min after administration. The (S)‐ketamine metabolites (S)‐norketamine, (S)‐dehydronorketamine, (2S,6R)‐hydroxynorketamine, (2S,5S)‐hydroxynorketamine and (2S,4S)‐hydroxynorketamine were also detected in both plasma and brain tissue. The enantioselectivity of the conversion of (S)‐ketamine and (R)‐ketamine to the respective (2,6)‐hydroxynorketamine metabolites was also investigated over the first 60 min after intravenous administration. (S)‐Ketamine produced significantly greater plasma and brain tissue concentrations of (2S,6S)‐hydroxynorketamine relative to the (2R,6R)‐hydroxynorketamine observed after the administration of (R)‐ketamine. However, the relative brain tissue: plasma concentrations of the enantiomeric (2,6)‐hydroxynorketamine metabolites were not significantly different indicating that the penetration of the metabolite is not enantioselective.
- 22 June 2015
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 3 (4) , e00157
Open AccessThe distribution and clearance of (2S,6S)‐hydroxynorketamine, an active ketamine metabolite, in Wistar rats
The distribution, clearance, and bioavailability of (2S,6S)‐hydroxynorketamine has been studied in the Wistar rat. The plasma and brain tissue concentrations over time of (2S,6S)‐hydroxynorketamine were determined after intravenous (20 mg/kg) and oral (20 mg/kg) administration of (2S,6S)‐hydroxynorketamine (n = 3). After intravenous administration, the pharmacokinetic parameters were estimated using noncompartmental analysis and the half‐life of drug elimination during the terminal phase (t1/2) was 8.0 ± 4.0 h and the apparent volume of distribution (Vd) was 7352 ± 736 mL/kg, clearance (Cl) was 704 ± 139 mL/h per kg, and the bioavailability was 46.3%. Significant concentrations of (2S,6S)‐hydroxynorketamine were measured in brain tissues at 10 min after intravenous administration, ~30 μg/mL per g tissue which decreased to 6 μg/mL per g tissue at 60 min. The plasma and brain concentrations of (2S,6S)‐hydroxynorketamine were also determined after the intravenous administration of (S)‐ketamine, where significant plasma and brain tissue concentrations of (2S,6S)‐hydroxynorketamine were observed 10 min after administration. The (S)‐ketamine metabolites (S)‐norketamine, (S)‐dehydronorketamine, (2S,6R)‐hydroxynorketamine, (2S,5S)‐hydroxynorketamine and (2S,4S)‐hydroxynorketamine were also detected in both plasma and brain tissue. The enantioselectivity of the conversion of (S)‐ketamine and (R)‐ketamine to the respective (2,6)‐hydroxynorketamine metabolites was also investigated over the first 60 min after intravenous administration. (S)‐Ketamine produced significantly greater plasma and brain tissue concentrations of (2S,6S)‐hydroxynorketamine relative to the (2R,6R)‐hydroxynorketamine observed after the administration of (R)‐ketamine. However, the relative brain tissue: plasma concentrations of the enantiomeric (2,6)‐hydroxynorketamine metabolites were not significantly different indicating that the penetration of the metabolite is not enantioselective.
- Open Access
- 21 October 2014
- Published by Taylor & Francis in Expert Review of Neurotherapeutics
- Vol. 14 (11) , 1239-1242
What is hydroxynorketamine and what can it bring to neurotherapeutics?
(R,S)-Ketamine was initially developed as an anesthetic agent and its pharmacological properties were determined on the basis of this clinical use. However, pharmacological studies in rat led to the development of the ‘Ketamine Paradigm’, whereby (R,S)-ketamine and its N-demethylated metabolite (R,S)-norketamine were deemed the active compounds whereas the other ketamine metabolites were considered inactive. Recent in vivo and in vitro studies with (2S,6S)-hydroxynorketamine, a previously identified ‘inactive’ metabolite, have demonstrated that this compound is an active and selective inhibitor of the α7 subtype of the nicotinic acetylcholine receptor and that this activity contributes to the pharmacological responses associated with the antidepressant activity of (R,S)-ketamine. Thus, it appears that it is necessary to reassess the ‘Ketamine Paradigm’ in regards to the use of sub-anesthetic doses of (R,S)-ketamine in the treatment of treatment-resistant depression.
- 21 October 2014
- Published by Taylor & Francis in Expert Review of Neurotherapeutics
- Vol. 14 (11) , 1239-1242
Open AccessWhat is hydroxynorketamine and what can it bring to neurotherapeutics?
(R,S)-Ketamine was initially developed as an anesthetic agent and its pharmacological properties were determined on the basis of this clinical use. However, pharmacological studies in rat led to the development of the ‘Ketamine Paradigm’, whereby (R,S)-ketamine and its N-demethylated metabolite (R,S)-norketamine were deemed the active compounds whereas the other ketamine metabolites were considered inactive. Recent in vivo and in vitro studies with (2S,6S)-hydroxynorketamine, a previously identified ‘inactive’ metabolite, have demonstrated that this compound is an active and selective inhibitor of the α7 subtype of the nicotinic acetylcholine receptor and that this activity contributes to the pharmacological responses associated with the antidepressant activity of (R,S)-ketamine. Thus, it appears that it is necessary to reassess the ‘Ketamine Paradigm’ in regards to the use of sub-anesthetic doses of (R,S)-ketamine in the treatment of treatment-resistant depression.
- 11 September 2014
- Published by Springer Nature in Psychopharmacology
- Vol. 231 (20) , 4083-4084
Are basal D-serine plasma levels a predictive biomarker for the rapid antidepressant effects of ketamineand ketamine metabolites?
- 11 September 2014
- Published by Springer Nature in Psychopharmacology
- Vol. 231 (20) , 4083-4084
Are basal D-serine plasma levels a predictive biomarker for the rapid antidepressant effects of ketamineand ketamine metabolites?
- 24 July 2014
- Published by Springer Nature in Psychopharmacology
- Vol. 232 (2) , 399-409
D-serine plasma concentration is a potential biomarker of (R,S)-ketamine antidepressant response in subjects with treatment-resistant depression
Rationale (R,S)-ketamine is a rapid and effective antidepressant drug that produces a response in two thirds of patients with treatment-resistant depression (TRD). The underlying biochemical differences between a (R,S)-ketamine responder (KET-R) and non-responder (KET-NR) have not been definitively identified but may involve serine metabolism. Objectives The aim of the study was to examine the relationship between baseline plasma concentrations of D-serine and its precursor L-serine and antidepressant response to (R,S)-ketamine in TRD patients. Methods Plasma samples were obtained from 21 TRD patients at baseline, 60 min before initiation of the (R,S)-ketamine infusion. Patients were classified as KET-Rs (n = 8) or KET-NRs (n = 13) based upon the difference in Montgomery–Åsberg Depression Rating Scale (MADRS) scores at baseline and 230 min after infusion, with response defined as a ≥50 % decrease in MADRS score. The plasma concentrations of D-serine and L-serine were determined using liquid chromatography-mass spectrometry. Results Baseline D-serine plasma concentrations were significantly lower in KET-Rs (3.02 ± 0.21 μM) than in KET-NRs (4.68 ± 0.81 μM), p < 0.001. A significant relationship between baseline D-serine plasma concentrations and percent change in MADRS at 230 min was determined using a Pearson correlation, r = 0.77, p < 0.001, with baseline D-serine explaining 60 % of the variance in (R,S)-ketamine response. The baseline concentrations of L-serine (L-Ser) in KET-Rs were also significantly lower than those measured in KET-NRs (66.2 ± 9.6 μM vs 242.9 ± 5.6 μM, respectively; p < 0.0001). Conclusions The results demonstrate that the baseline D-serine plasma concentrations were significantly lower in KET-Rs than in KET-NRs and suggest that this variable can be used to predict an antidepressant response following (R,S)-ketamine administration.
- 24 July 2014
- Published by Springer Nature in Psychopharmacology
- Vol. 232 (2) , 399-409
D-serine plasma concentration is a potential biomarker of (R,S)-ketamine antidepressant response in subjects with treatment-resistant depression
Rationale (R,S)-ketamine is a rapid and effective antidepressant drug that produces a response in two thirds of patients with treatment-resistant depression (TRD). The underlying biochemical differences between a (R,S)-ketamine responder (KET-R) and non-responder (KET-NR) have not been definitively identified but may involve serine metabolism. Objectives The aim of the study was to examine the relationship between baseline plasma concentrations of D-serine and its precursor L-serine and antidepressant response to (R,S)-ketamine in TRD patients. Methods Plasma samples were obtained from 21 TRD patients at baseline, 60 min before initiation of the (R,S)-ketamine infusion. Patients were classified as KET-Rs (n = 8) or KET-NRs (n = 13) based upon the difference in Montgomery–Åsberg Depression Rating Scale (MADRS) scores at baseline and 230 min after infusion, with response defined as a ≥50 % decrease in MADRS score. The plasma concentrations of D-serine and L-serine were determined using liquid chromatography-mass spectrometry. Results Baseline D-serine plasma concentrations were significantly lower in KET-Rs (3.02 ± 0.21 μM) than in KET-NRs (4.68 ± 0.81 μM), p < 0.001. A significant relationship between baseline D-serine plasma concentrations and percent change in MADRS at 230 min was determined using a Pearson correlation, r = 0.77, p < 0.001, with baseline D-serine explaining 60 % of the variance in (R,S)-ketamine response. The baseline concentrations of L-serine (L-Ser) in KET-Rs were also significantly lower than those measured in KET-NRs (66.2 ± 9.6 μM vs 242.9 ± 5.6 μM, respectively; p < 0.0001). Conclusions The results demonstrate that the baseline D-serine plasma concentrations were significantly lower in KET-Rs than in KET-NRs and suggest that this variable can be used to predict an antidepressant response following (R,S)-ketamine administration.
- Open Access
- 1 July 2014
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 121 (1) , 149-159
(R,S)-Ketamine Metabolites (R,S)-norketamine and (2S,6S)-hydroxynorketamine Increase the Mammalian Target of Rapamycin Function
Background: Subanesthetic doses of (R,S)-ketamine are used in the treatment of neuropathic pain and depression. In the rat, the antidepressant effects of (R,S)-ketamine are associated with increased activity and function of mammalian target of rapamycin (mTOR); however, (R,S)-ketamine is extensively metabolized and the contribution of its metabolites to increased mTOR signaling is unknown. Methods: Rats (n = 3 per time point) were given (R,S)-ketamine, (R,S)-norketamine, and (2S,6S)-hydroxynorketamine and their effect on the mTOR pathway determined after 20, 30, and 60 min. PC-12 pheochromocytoma cells (n = 3 per experiment) were treated with escalating concentrations of each compound and the impact on the mTOR pathway was determined. Results: The phosphorylation of mTOR and its downstream targets was significantly increased in rat prefrontal cortex tissue by more than ~2.5-, ~25-, and ~2-fold, respectively, in response to a 60-min postadministration of (R,S)-ketamine, (R,S)-norketamine, and (2S,6S)-hydroxynorketamine (P < 0.05, ANOVA analysis). In PC-12 pheochromocytoma cells, the test compounds activated the mTOR pathway in a concentration-dependent manner, which resulted in a significantly higher expression of serine racemase with ~2-fold increases at 0.05 nM (2S,6S)-hydroxynorketamine, 10 nM (R,S)-norketamine, and 1,000 nM (R,S)-ketamine. The potency of the effect reflected antagonistic activity of the test compounds at the α7-nicotinic acetylcholine receptor. Conclusions: The data demonstrate that (R,S)-norketamine and (2S,6S)-hydroxynorketamine have potent pharmacological activity both in vitro and in vivo and contribute to the molecular effects produced by subanesthetic doses of (R,S)-ketamine. The results suggest that the determination of the mechanisms underlying the antidepressant and analgesic effects of (R,S)-ketamine requires a full study of the parent compound and its metabolites.
- 1 July 2014
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 121 (1) , 149-159
Open Access(R,S)-Ketamine Metabolites (R,S)-norketamine and (2S,6S)-hydroxynorketamine Increase the Mammalian Target of Rapamycin Function
Background: Subanesthetic doses of (R,S)-ketamine are used in the treatment of neuropathic pain and depression. In the rat, the antidepressant effects of (R,S)-ketamine are associated with increased activity and function of mammalian target of rapamycin (mTOR); however, (R,S)-ketamine is extensively metabolized and the contribution of its metabolites to increased mTOR signaling is unknown. Methods: Rats (n = 3 per time point) were given (R,S)-ketamine, (R,S)-norketamine, and (2S,6S)-hydroxynorketamine and their effect on the mTOR pathway determined after 20, 30, and 60 min. PC-12 pheochromocytoma cells (n = 3 per experiment) were treated with escalating concentrations of each compound and the impact on the mTOR pathway was determined. Results: The phosphorylation of mTOR and its downstream targets was significantly increased in rat prefrontal cortex tissue by more than ~2.5-, ~25-, and ~2-fold, respectively, in response to a 60-min postadministration of (R,S)-ketamine, (R,S)-norketamine, and (2S,6S)-hydroxynorketamine (P < 0.05, ANOVA analysis). In PC-12 pheochromocytoma cells, the test compounds activated the mTOR pathway in a concentration-dependent manner, which resulted in a significantly higher expression of serine racemase with ~2-fold increases at 0.05 nM (2S,6S)-hydroxynorketamine, 10 nM (R,S)-norketamine, and 1,000 nM (R,S)-ketamine. The potency of the effect reflected antagonistic activity of the test compounds at the α7-nicotinic acetylcholine receptor. Conclusions: The data demonstrate that (R,S)-norketamine and (2S,6S)-hydroxynorketamine have potent pharmacological activity both in vitro and in vivo and contribute to the molecular effects produced by subanesthetic doses of (R,S)-ketamine. The results suggest that the determination of the mechanisms underlying the antidepressant and analgesic effects of (R,S)-ketamine requires a full study of the parent compound and its metabolites.
- Open Access
- 28 March 2014
- Published by Wiley in British Journal of Pharmacology
- Vol. 171 (8) , 2230-2242
A pilot study of plasma metabolomic patterns from patients treated with ketamine for bipolar depression: evidence for a response‐related difference in mitochondrial networks
Background and Purpose: (R,S)‐ketamine produces rapid and significant antidepressant effects in approximately 65% of patients suffering from treatment‐resistant bipolar depression (BD). The genetic, pharmacological and biochemical differences between ketamine responders and non‐responders have not been identified. The purpose of this study was to employ a metabolomics approach, a global, non‐targeted determination of endogenous metabolic patterns, to identify potential markers of ketamine response and non‐response.Experimental Approach: Plasma samples from 22 BD patients were analyzed to produce metabolomic patterns. The patients had received ketamine in a placebo‐controlled crossover study and the samples were obtained 230 min post‐administration at which time the patients were categorized as responders or non‐responders. Matching plasma samples from the placebo arm of the study were also analysed. During the study, the patients were maintained on either lithium or valproate.Key Results: The metabolomic patterns were significantly different between the patients maintained on lithium and those maintained on valproate, irrespective of response to ketamine. In the patients maintained on lithium, 18 biomarkers were identified. In responders, lysophosphatidylethanolamines (4) and lysophosphatidylcholines (9) were increased relative to non‐responders.Conclusions and Implications: The results indicate that the differences between patients who respond to ketamine and those who do not are due to alterations in the mitochondrial β‐oxidation of fatty acids. These differences were not produced by ketamine administration. The data indicate that pretreatment metabolomics screening may be a guide to the prediction of response and a potential approach to the individualization of ketamine therapy.Linked Articles: This article is part of a themed issue on Mitochondrial Pharmacology: Energy, Injury & Beyond. To view the other articles in this issue visit http://dx.doi.org/10.1111/bph.2014.171.issue‐8
- 28 March 2014
- Published by Wiley in British Journal of Pharmacology
- Vol. 171 (8) , 2230-2242
Open AccessA pilot study of plasma metabolomic patterns from patients treated with ketamine for bipolar depression: evidence for a response‐related difference in mitochondrial networks
Background and Purpose: (R,S)‐ketamine produces rapid and significant antidepressant effects in approximately 65% of patients suffering from treatment‐resistant bipolar depression (BD). The genetic, pharmacological and biochemical differences between ketamine responders and non‐responders have not been identified. The purpose of this study was to employ a metabolomics approach, a global, non‐targeted determination of endogenous metabolic patterns, to identify potential markers of ketamine response and non‐response.Experimental Approach: Plasma samples from 22 BD patients were analyzed to produce metabolomic patterns. The patients had received ketamine in a placebo‐controlled crossover study and the samples were obtained 230 min post‐administration at which time the patients were categorized as responders or non‐responders. Matching plasma samples from the placebo arm of the study were also analysed. During the study, the patients were maintained on either lithium or valproate.Key Results: The metabolomic patterns were significantly different between the patients maintained on lithium and those maintained on valproate, irrespective of response to ketamine. In the patients maintained on lithium, 18 biomarkers were identified. In responders, lysophosphatidylethanolamines (4) and lysophosphatidylcholines (9) were increased relative to non‐responders.Conclusions and Implications: The results indicate that the differences between patients who respond to ketamine and those who do not are due to alterations in the mitochondrial β‐oxidation of fatty acids. These differences were not produced by ketamine administration. The data indicate that pretreatment metabolomics screening may be a guide to the prediction of response and a potential approach to the individualization of ketamine therapy.Linked Articles: This article is part of a themed issue on Mitochondrial Pharmacology: Energy, Injury & Beyond. To view the other articles in this issue visit http://dx.doi.org/10.1111/bph.2014.171.issue‐8
- 1 February 2014
- Published by Elsevier in Biochemical Pharmacology
- Vol. 87 (4) , 547-561
(R,R′)-4′-methoxy-1-naphthylfenoterol targets GPR55-mediated ligand internalization and impairs cancer cell motility
- 1 February 2014
- Published by Elsevier in Biochemical Pharmacology
- Vol. 87 (4) , 547-561
(R,R′)-4′-methoxy-1-naphthylfenoterol targets GPR55-mediated ligand internalization and impairs cancer cell motility
- 1 December 2013
- Published by Elsevier in Cellular Signalling
- Vol. 25 (12) , 2634-2645
Nicotinic acetylcholine receptor antagonists alter the function and expression of serine racemase in PC-12 and 1321N1 cells
- 1 December 2013
- Published by Elsevier in Cellular Signalling
- Vol. 25 (12) , 2634-2645
Nicotinic acetylcholine receptor antagonists alter the function and expression of serine racemase in PC-12 and 1321N1 cells